Related Experiment Video

Updated: May 25, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in

Chien-Feng Li1, Ju-Ming Wang, Hong-Yo Kang

  • 1Department of Pathology, National Institute of Cancer Research, Taiwan.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 11, 2012
PubMed
Abstract

Insights

SKP2 amplification drives aggressive myxofibrosarcoma by increasing protein overexpression. Bortezomib shows therapeutic potential by targeting the ubiquitin-proteasome pathway and reducing SKP2 levels.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Myxofibrosarcoma (MF) is a soft tissue sarcoma with poorly understood molecular drivers of clinical aggressiveness.
  • Identifying key molecular determinants is crucial for improving patient outcomes and developing targeted therapies.

Purpose of the Study:

  • To elucidate the role of SKP2 amplification in the molecular pathogenesis and clinical aggressiveness of myxofibrosarcoma.
  • To investigate the therapeutic potential of bortezomib in targeting SKP2-driven myxofibrosarcoma.

Main Methods:

  • Array comparative genomic hybridization (aCGH) was used to identify gene amplifications in myxofibrosarcoma samples and cell lines.
  • SKP2 gene dosage was correlated with clinical parameters in 82 independent tumors.
  • SKP2 knockdown and pharmacologic assays with bortezomib were performed in vitro and in vivo.

Main Results:

  • SKP2 amplification was identified in 38% of myxofibrosarcoma tumors, associated with SKP2 overexpression and adverse prognosticators.
  • SKP2 knockdown suppressed proliferation, migration, and invasion, downregulating motility-promoting genes.
  • Bortezomib reduced SKP2 expression, induced apoptosis, and inhibited tumor growth in vivo, demonstrating therapeutic efficacy.

Conclusions:

  • SKP2 amplification is a predominant mechanism driving tumor aggressiveness in myxofibrosarcoma.
  • Myxofibrosarcoma cells are sensitive to bortezomib, highlighting the ubiquitin-proteasome pathway as a potential therapeutic target.

More Related Videos

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...